A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Sponsor: Wugen, Inc.
This PHASE1 trial investigates Acute Myeloid Leukemia and is currently completed. Wugen, Inc. leads this study, which shows 13 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Wugen, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .